Novo Nordisk strikes $3.3 billion deal to buy research partner Dicerna Pharmaceuticals
Marketwatch -

Novo Nordisk said it's buying Dicerna Pharmaceuticals for $3.3 billion, or $38.25 per share in cash. Dicerna ended Wednesday at $21.28. Novo Nordisk already had a research collaboration with Dicerna, and said the deal is part of a strategy of using a broad range of technology platforms applicable across all Novo Nordisk's therapeutic focus areas. The existing collaboration between Novo Nordisk and Dicerna encompassed the exploration of more than 30 liver cell targets. Novo Nordisk said the...

Read this story at

Loading...

Related Articles